SCHEMBL24917470

SCHEMBL24917470

C#CCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.67
▸ ALDH1A1 P00352 2/20 0.56
▸ THRB P10828 1/20 0.56
▸ LGALS8 O00214 1/20 0.53
▸ LGALS3 P17931 1/20 0.53
▸ LGALS4 P56470 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ CD69 Q07108 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ B4GALT1 P15291 1/20 0.46
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25344300 0.93 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL25343369 0.93 MAPK1 (0.71) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL13849179 0.87 MAPK1 (0.62) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL25868457 0.87 MAPK1 (0.62) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL12792638 0.87 MAPK1 (0.62) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL24299984 0.86 MAPK1 (0.61) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL17400175 0.85 MAPK1 (0.74) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL12319827 0.85 MAPK1 (0.74) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL15159538 0.85 MAPK1 (0.74) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL16628272 0.84 MAPK1 (0.81) MAPK1ALDH1A1THRBLGALS8LGALS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250101007-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. 2025-03-27 — — US disclosed
EP-4370157-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2024-05-22 — — EP disclosed
US-20230250091-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. 2023-08-10 — — US disclosed
US-20230250091-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. 2023-08-10 — — US disclosed
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates LYCIA THERAPEUTICS, INC. 2023-05-25 — — US disclosed
WO-2023288033-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2023-01-19 — — WO disclosed
WO-2023288033-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2023-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates M6PR, ASGR1, IGF2R MAPK1 2043/4885ALDH1A1 3655/4885THRB 1793/4885
US-20250101007-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES ASGR1, LAMP2, FCGR2A MAPK1 2970/4885ALDH1A1 2955/4885THRB 1561/4885
US-20230250091-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES ASGR1, LAMP2, FCGR2A MAPK1 2970/4885ALDH1A1 2955/4885THRB 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback